FMRD; HLRCC; LRCC; MCL; MCUL1
The FH gene is associated with autosomal dominant hereditary leiomyomatosis and renal cell cancer (HLRCC) (MedGen UID: 353771) and autosomal recessive fumarate hydratase deficiency (FHD) (MedGen UID: 87458).
Order this gene as a single gene test.
Invitae tests that include this gene:
The FH gene encodes fumarate hydratase, also called fumarase, an enzyme that converts fumarate to malate as part of the Krebs cycle.
FH – hereditary leiomyomatosis and renal cell cancer (HLRCC)
MedGen UID: 353771
HLRCC is a rare, adult-onset tumor-predisposition syndrome that is characterized by cutaneous leiomyomas, uterine leiomyomas, and renal tumors. Cutaneous leiomyomas appear as skin-colored or light-brown papules that can develop over the trunk, extremities, and occasionally the face. They are often more sensitive than the surrounding skin to cold or light touch, and may be painful. They present in the second to fourth decade of life and tend to increase in size and number over time (PMID: 25012257, 20301430, 12772087).
In addition, uterine leiomyomas (fibroids) are present in almost all females with HLRCC, but they rarely become malignant. Uterine fibroids are very common in the general population, but the fibroids in HLRCC tend to be numerous and have an earlier onset than in the general population. Symptoms include irregular or heavy menstruation and pelvic pain (PMID: 25012257, 20301430).
Approximately 15% of individuals with HLRCC develop renal tumors, including type 2 papillary, tubulo-papillary, collecting-duct carcinoma, and possibly Wilms tumor. Renal tumors in HLRCC are typically unilateral, solitary, and aggressive. Symptoms include hematuria, lower back pain, and a palpable mass, although some have no symptoms until the disease is advanced (PMID: 25012257, 20301430, 25018647).
Invitae considers FH a “preliminary evidence” gene in its association with paragangliomas and pheochromocytomas (PMID: 25004247, 24334767). preliminary evidence genes are selected from an extensive review of the literature and expert recommendations, but the association between the gene and the specific condition has not been completely established. This uncertainty may be resolved as new information becomes available, and therefore clinicians may continue to order these preliminary evidence genes.
FH is a tumor suppressor gene, meaning its function is to help control the rate of growth and cell division in the body. The protein encoded by this gene is an enzymatic component of the tricarboxylic acid (TCA) cycle, or Krebs cycle, and catalyzes the formation of L-malate from fumarate ( Gene. Gene ID: 2271. Accessed September 2015). UniProt consortium, UniprotKB – P07954 (FUMH_HUMAN). If there is a pathogenic variant in this gene that prevents it from functioning normally in DNA repair, the risk of developing certain types of cancers is increased.
Variants in the HLRCC gene have autosomal dominant inheritance. This means that an individual with a pathogenic variant has a 50% chance of passing the condition on to their offspring. Once a pathogenic mutation is detected in an individual, it is possible to identify at-risk relatives who can pursue testing for this specific familial variant. Many cases are inherited from a parent, but some cases can occur spontaneously (i.e., an individual with a pathogenic variant has parents who do not have it) (PMID: 20301430).
Individuals with a pathogenic variant in the FH gene are also carriers of a condition called fumarase deficiency (also known as fumarate hydratase deficiency and fumaric aciduria). This is an autosomal recessive condition that results when an individual inherits a pathogenic FH variant from each parent. Fumarase deficiency is an inborn error of metabolism that is characterized by rapidly progressive neurologic impairment, including hypotonia, seizures, and cerebral atrophy. Most survive only for a few months after birth ( NCBI Genetics Home Reference. Fumarase deficiency. http://ghr.nlm.nih.gov/condition/fumarase-deficiency. Accessed September 2015; PMID: 20549362, 21560188). For there to be a risk to offspring of fumarate hydratase, both the patient and their partner would have to have a single pathogenic variant in FH; in such a case, the risk to offspring is 25%.
An individual’s cancer risk and medical management are not determined by genetic test results alone. Overall cancer risk assessment incorporates additional factors, including personal medical history, family history, and any available genetic information that may result in a personalized plan for cancer prevention and surveillance.
Even though the data regarding FH variants are limited, knowing if a pathogenic variant is present is advantageous. At-risk relatives can be identified, enabling pursuit of a diagnostic evaluation. Further, the available information regarding hereditary cancer susceptibility genes is constantly evolving and more clinically relevant data regarding FH are likely to become available in the near future. Awareness of this cancer predisposition encourages patients and their providers to inform at-risk family members, to consider implementing suggested screening protocols, and to be vigilant in maintaining close and regular contact with their local genetics clinic in anticipation of new information.
Review date: September 2015
Invitae is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified clinical diagnostic laboratory performing full-gene sequencing and deletion/duplication analysis using next-generation sequencing technology (NGS).
Our sequence analysis covers clinically important regions of each gene, including coding exons and 10 to 20 base pairs of adjacent intronic sequence on either side of the coding exons in the transcript listed below. In addition, the analysis covers the select non-coding variants specifically defined in the table below. Any variants that fall outside these regions are not analyzed. Any limitations in the analysis of these genes will be listed on the report. Contact client services with any questions.
Based on validation study results, this assay achieves >99% analytical sensitivity and specificity for single nucleotide variants, insertions and deletions <15bp in length, and exon-level deletions and duplications. Invitae's methods also detect insertions and deletions larger than 15bp but smaller than a full exon but sensitivity for these may be marginally reduced. Invitae’s deletion/duplication analysis determines copy number at a single exon resolution at virtually all targeted exons. However, in rare situations, single-exon copy number events may not be analyzed due to inherent sequence properties or isolated reduction in data quality. Certain types of variants, such as structural rearrangements (e.g. inversions, gene conversion events, translocations, etc.) or variants embedded in sequence with complex architecture (e.g. short tandem repeats or segmental duplications), may not be detected. Additionally, it may not be possible to fully resolve certain details about variants, such as mosaicism, phasing, or mapping ambiguity. Unless explicitly guaranteed, sequence changes in the promoter, non-coding exons, and other non-coding regions are not covered by this assay. Please consult the test definition on our website for details regarding regions or types of variants that are covered or excluded for this test. This report reflects the analysis of an extracted genomic DNA sample. In very rare cases, (circulating hematolymphoid neoplasm, bone marrow transplant, recent blood transfusion) the analyzed DNA may not represent the patient's constitutional genome.
|Gene||Transcript reference||Sequencing analysis||Deletion/Duplication analysis|